#China #Shanghai #Wound Care #Mölnlycke #Zhende Medical

Collaboration between Mölnlycke and Zhende Medical

Mölnlycke Health Care, a global frontrunner in the field of MedTech, has recently formed a strategic partnership with Zhende Medical, a prominent name in medical supplies within China. This collaboration marks a pivotal moment in the advancement of wound care solutions, particularly as both companies have united their expertise to create a joint venture aimed at improving access to innovative wound care treatments in China.

The Need for Advanced Wound Care

As China’s healthcare landscape evolves, so does the necessity for advanced medical interventions, particularly in wound care. The demand is fueled by an increase in chronic illnesses, a growing elderly population, and an overall expansion in health-related economic activities. As per estimates, the Chinese advanced wound dressing market is valued at approximately EUR 380 million (or roughly RMB 3 billion), revealing a significant opportunity for medical innovators.

The Joint Venture Overview

The newly established entity, operating under the name Mölnlycke Zhende (Shanghai) Medical Technology Co Ltd, will primarily focus on leveraging the combined strengths and portfolios of both companies. Mölnlycke is known for its proprietary Safetac® technology and its extensive experience spanning over 175 years in advanced wound care.

Zhende Medical, on the other hand, contributes with its own extensive range of innovative wound care solutions that include advanced products for burns, vitiligo treatments, and chronic wound management.

The joint venture promises a wide-reaching commercial strategy that encompasses nearly 10,000 hospitals and 200,000 pharmacies throughout China. Additionally, the collaboration will tap into eCommerce platforms to enhance accessibility for patients and healthcare providers.

Strategic Advantages

With Mölnlycke holding a majority stake in the new venture, the initiative signifies a localized approach to advanced wound care. The aim is to blend global expertise with local insights, thereby efficiently addressing the unique needs of the Chinese healthcare market. This arrangement is expected to accelerate growth in product availability, ultimately leading to improved patient outcomes.

Guillaume Joucla, the Interim CEO of Mölnlycke Health Care, commented, "This joint venture represents an important milestone in the growth journey of both Mölnlycke and Zhende Medical. By joining forces, we are strengthening our presence in China, expanding our wound care portfolio..."

Future Prospects

The joint venture is poised to launch its operations in the third quarter of 2026, initially concentrating on the sales and distribution of both parties' advanced wound care products. Over time, there are intentions to explore co-development opportunities for new products.

The partnership underscores a commitment to sustainability, adhering to both Mölnlycke's and Zhende Medical's global sustainability goals. This initiative thus sets a high standard not just for product offerings but also for ethical business conduct in the evolving medical landscape in China.

Conclusion

In summary, the collaboration between Mölnlycke Health Care and Zhende Medical presents a compelling opportunity to revolutionize wound care competency in China. By harnessing their combined resources and know-how, the two companies aim to elevate treatment standards, ensuring better health outcomes for patients across the nation.